Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.85 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.85 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.85 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.85 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.68 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.68 |
| ▸ | ERN2 | Q76MJ5 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876061 | 0.95 | PIK3CB (0.77) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1871915 | 0.94 | PIK3CB (0.76) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1870748 | 0.93 | PIK3CB (0.74) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1865479 | 0.92 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1871630 | 0.92 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1864697 | 0.92 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1868829 | 0.92 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1869541 | 0.92 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1870796 | 0.92 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1869718 | 0.91 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021001431-A1 | USE OF PI3KA-SELECTIVE INHIBITORS FOR TREATING METASTATIC DISEASE IN PATIENTS SUFFERING FROM PANCREATIC CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-01-07 | — | — | WO | disclosed |
| EP-3350346-A1 | NOVEL BIOMARKERS AND METHODS OF TREATING CANCER | Astrazeneca AB (SE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046394-A1 | NOVEL BIOMARKERS AND METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |